Hainan Poly Pharm. Co., Ltd

As of September 30, 2024, Hainan Poly Pharm. Co., Ltd has 451.78M shares outstanding.

As of September 30, 2024, Hainan Poly Pharm. Co., Ltd trades at a trailing price-to-earnings ratio of 52.12. The price-to-sales ratio is 3.86, and the price-to-book ratio stands at 3.12.

As of September 30, 2024, Hainan Poly Pharm. Co., Ltd trades at an EV/EBITDA multiple of 74.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 74.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Hainan Poly Pharm. Co., Ltd trades at an EV/FCF ratio of 159.58, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of September 30, 2024, Hainan Poly Pharm. Co., Ltd maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 96.76, indicating elevated leverage, while an interest coverage ratio of 3.12 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended September 30, 2024, Hainan Poly Pharm. Co., Ltd posted a negative return on equity (ROE) of -6.34, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -19.26, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -1.69, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -10.12, pointing to unprofitable operations over the period. Inventory turnover of 0.71 indicates how many times Hainan Poly Pharm. Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended September 30, 2024. That works out to an effective tax rate of 1,143.31, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on May 22, 2025, Hainan Poly Pharm. Co., Ltd's stock has declined approximately 92.79% over the past 52 weeks. The 50-day moving average sits at 2.01, while the 200-day moving average is 6.39.

Over the twelve months ended September 30, 2024, Hainan Poly Pharm. Co., Ltd posted a gross margin of 72.05, reflecting its pricing power and cost economics. The operating margin of 7.64 and net profit margin of -8.12 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2024. The dividend payout ratio of -69.43 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.30, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.87, meaning Hainan Poly Pharm. Co., Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hainan Poly Pharm. Co., Ltd's most recent stock split took place on July 3, 2020 with a 40000:61287 split ratio.

As of September 30, 2024, Hainan Poly Pharm. Co., Ltd has an Altman Z-Score of 1.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.